Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 01 February, 2012 and appeared in  MedicationType 2 DiabetesIssue 611

FDA Approves Eli Lilly Diabetes Combo Drug Jentadueto

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the FDA approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets....

Advertisement

Drawing from the momentum of Tradjenta™ (linagliptin) tablets -- approved for U.S. marketing in May 2011 – JENTADUETO combines linagliptin and metformin into a new, single-tablet option, taken twice daily and comes in 3 different dosages.

JENTADUETO is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. JENTADUETO is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.

At the maximum dose, JENTADUETO demonstrated placebo-corrected reductions in hemoglobin A1Clevels of up to 1.7 percent. It can be used alone or in combination with a sulfonylurea, another commonly prescribed medication for type 2 diabetes.

The JENTADUETO label contains a boxed warning because the addition of metformin which may cause a rare but serious condition called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. It is not for treatment of type 1 diabetes or diabetic ketoacidosis and has not been studied in combination with insulin. The dosage should be individualized based on the patient's current regimen and the maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin twice a day. It should be given twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

It comes in 3 dosage forms, 2.5 mg linagliptin/500 mg metformin hydrochloride, 2.5 mg linagliptin/850 mg metformin hydrochloride and 2.5 mg linagliptin/1000 mg metformin hydrochloride.

Contraindications include: renal impairment, metabolic acidosis and hypersensitivity to linagliptin or metformin.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company news release

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 01 February, 2012 and appeared in  MedicationType 2 DiabetesIssue 611

Past five issues: Issue 747 | Diabetes Clinical Mastery Series Issue 206 | SGLT-2 Inhibitors Special Edition September 2014 | Issue 746 | Diabetes Clinical Mastery Series Issue 205 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
Pistachios Associated with an Improved Metabolic Risk Profile in Prediabetes
Posted August 29, 2014
New Ultra-Rapid-Acting Insulin Formulation
Posted August 22, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
Sensor Implant Measures Blood pH in Type 1 Diabetes
Posted August 29, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology



Search Articles On Diabetes In Control